Terms: = Leukemia AND MYB, c-myb_CDS, 4602, ENSG00000118513, P10242, efg, Cmyb, c-myb
539 results:
1. Foetal haemoglobin elevation, unfavourable prognosis, and protective role of genetic variants
Borrayo-LóPez FJ; Ibarra-Cortés B; Perea-Díaz F; MuñOz-Zúñiga AI; Montoya-Fuentes H; Soto-Padilla JM; Rizo-De La Torre LDC
J Genet; 2024; 103():. PubMed ID: 38736250
[TBL] [Abstract] [Full Text] [Related]
2. Transcription Factor myb as Therapeutic Target: Current Developments.
Klempnauer KH
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542205
[TBL] [Abstract] [Full Text] [Related]
3. Acquired immune resistance is associated with interferon signature and modulation of KLF6/c-myb transcription factors in myeloid leukemia.
Parveen M; Karaosmanoglu B; Sucularli C; Uner A; Taskiran EZ; Esendagli G
Eur J Immunol; 2024 May; 54(5):e2350717. PubMed ID: 38462943
[TBL] [Abstract] [Full Text] [Related]
4. Integrated analysis of transcriptome and genome variations in pediatric T cell acute lymphoblastic leukemia: data from north Indian tertiary care center.
Singh M; Sharma P; Bhatia P; Trehan A; Thakur R; Sreedharanunni S
BMC Cancer; 2024 Mar; 24(1):325. PubMed ID: 38459434
[TBL] [Abstract] [Full Text] [Related]
5. Transcriptome Analysis in Mexican Adults with Acute Lymphoblastic leukemia.
Cruz-Miranda GM; Olarte-Carrillo I; Bárcenas-López DA; Martínez-Tovar A; Ramírez-Bello J; Ramos-Peñafiel CO; García-Laguna AI; Cerón-Maldonado R; May-Hau D; Jiménez-Morales S
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339034
[TBL] [Abstract] [Full Text] [Related]
6. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
Mill CP; Fiskus WC; DiNardo CD; Reville P; Davis JA; Birdwell CE; Das K; Hou H; Takahashi K; Flores L; Ruan X; Su X; Loghavi S; Khoury JD; Bhalla KN
Blood Cancer J; 2024 Feb; 14(1):25. PubMed ID: 38316746
[TBL] [Abstract] [Full Text] [Related]
7. Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia.
Noura M; Matsuo H; Yasuda T; Tsuzuki S; Kiyoi H; Hayakawa F
Oncogene; 2024 Feb; 43(6):447-456. PubMed ID: 38102337
[TBL] [Abstract] [Full Text] [Related]
8. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
Birdwell CE; Fiskus W; Kadia TM; Mill CP; Sasaki K; Daver N; DiNardo CD; Pemmaraju N; Borthakur G; Davis JA; Das K; Sharma S; Horrigan S; Ruan X; Su X; Khoury JD; Kantarjian H; Bhalla KN
Leukemia; 2024 Mar; 38(3):545-556. PubMed ID: 38086946
[TBL] [Abstract] [Full Text] [Related]
9. Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia.
Hoffmeister LM; Suttorp J; Walter C; Antoniou E; Behrens YL; Göhring G; Awada A; von Neuhoff N; Reinhardt D; Schneider M
Leukemia; 2024 Mar; 38(3):538-544. PubMed ID: 38086945
[TBL] [Abstract] [Full Text] [Related]
10. Inhibition of CREB Binding and Function with a Dual-Targeting Ligand.
Liu Y; Joy ST; Henley MJ; Croskey A; Yates JA; Merajver SD; Mapp AK
Biochemistry; 2024 Jan; 63(1):1-8. PubMed ID: 38086054
[TBL] [Abstract] [Full Text] [Related]
11. Reversal of myb-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML.
Negri A; Ward C; Bucci A; D'Angelo G; Cauchy P; Radesco A; Ventura AB; Walton DS; Clarke M; Mandriani B; Pappagallo SA; Mondelli P; Liao K; Gargano G; Zaccaria GM; Viggiano L; Lasorsa FM; Ahmed A; Di Molfetta D; Fiermonte G; Cives M; Guarini A; Vegliante MC; Ciavarella S; Frampton J; Volpe G
Cell Death Dis; 2023 Nov; 14(11):763. PubMed ID: 37996430
[TBL] [Abstract] [Full Text] [Related]
12. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Nicosia L; Spencer GJ; Brooks N; Amaral FMR; Basma NJ; Chadwick JA; Revell B; Wingelhofer B; Maiques-Diaz A; Sinclair O; Camera F; Ciceri F; Wiseman DH; Pegg N; West W; Knurowski T; Frese K; Clegg K; Campbell VL; Cavet J; Copland M; Searle E; Somervaille TCP
Cancer Cell; 2023 Dec; 41(12):2136-2153.e13. PubMed ID: 37995682
[TBL] [Abstract] [Full Text] [Related]
13. From modulation of cellular plasticity to potentiation of therapeutic resistance: new and emerging roles of myb transcription factors in human malignancies.
Anand S; Vikramdeo KS; Sudan SK; Sharma A; Acharya S; Khan MA; Singh S; Singh AP
Cancer Metastasis Rev; 2024 Mar; 43(1):409-421. PubMed ID: 37950087
[TBL] [Abstract] [Full Text] [Related]
14. S1P-S1PR3-RAS promotes the progression of S1PR3
Zhu D; Jiang T; Ma D; Zhang H; Zhang J; Lv W; Gong M; Wang H; Liu Z; Su H; Zeng L; Liu S; Tang S; Yang B; Tshavuka FI; Fu G; Liu Z; Peng D; Liu H; Yan Z; Cao Z; Zhao H; He TC; Yu J; Shu Y; Zou L
Leukemia; 2023 Oct; 37(10):1982-1993. PubMed ID: 37591940
[TBL] [Abstract] [Full Text] [Related]
15. Analysis of single-cell sequencing results of an elderly patient with myeloid leukemia reveals high expression of multiple oncogenes in monocytes and hematopoietic stem cells.
Xu X; Xiong M; Ye H; Qi Y; Zhao Y
Hematology; 2023 Dec; 28(1):2240129. PubMed ID: 37535066
[TBL] [Abstract] [Full Text] [Related]
16. Increased myb alternative promoter usage is associated with relapse in acute lymphoblastic leukemia.
Fehr A; Arvidsson G; Nordlund J; Lönnerholm G; Stenman G; Andersson MK
Genes Chromosomes Cancer; 2023 Oct; 62(10):597-606. PubMed ID: 37218648
[TBL] [Abstract] [Full Text] [Related]
17. A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.
Wilde L; Porazzi P; Trotta R; De Dominici M; Palmisiano N; Keiffer G; Rancani K; Yingling K; Calabretta B; Kasner M
Leuk Res; 2023 Jun; 129():107075. PubMed ID: 37079999
[TBL] [Abstract] [Full Text] [Related]
18. C/EBPβ cooperates with myb to maintain the oncogenic program of AML cells.
Klempnauer KH
Oncotarget; 2023 Mar; 14():174-177. PubMed ID: 36913305
[TBL] [Abstract] [Full Text] [Related]
19. A fetal tumor suppressor axis abrogates MLL-fusion-driven acute myeloid leukemia.
Eldeeb M; Yuan O; Guzzi N; Thi Ngoc PC; Konturek-Ciesla A; Kristiansen TA; Muthukumar S; Magee J; Bellodi C; Yuan J; Bryder D
Cell Rep; 2023 Feb; 42(2):112099. PubMed ID: 36763502
[TBL] [Abstract] [Full Text] [Related]
20. Harnessing the myb-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
Smith C; Touzart A; Simonin M; Tran-Quang C; Hypolite G; Latiri M; Andrieu GP; Balducci E; Dourthe MÉ; Goyal A; Huguet F; Petit A; Ifrah N; Baruchel A; Dombret H; Macintyre E; Plass C; Ghysdael J; Boissel N; Asnafi V
Mol Cancer; 2023 Jan; 22(1):12. PubMed ID: 36650499
[TBL] [Abstract] [Full Text] [Related]
[Next]
